Phase 3 randomized controlled trials

FDA Approves Tucatinib as Chemotherapy‑Free Maintenance for Advanced HER2‑Positive Breast Cancer

The agency based the approval on HER2CLIMB-05 data showing a meaningful progression-free survival gain with tucatinib while the label warns of severe hepatotoxicity and overall survival data remain immature.